Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment
Life sciences
6 May 2024
As Nanobacterie prepares for clinical trials, EPEI’s investment both validates their innovative approach and strengthens their ability to address critical global medical challenges.
EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.
Founded in 2008 by Dr. Edouard Alphandéry, a leading expert in oncological hyperthermia, Nanobacterie specializes in non-invasive cancer treatments utilizing magnetic nanoparticles synthesized by magnetotactic bacteria. The company has been at the forefront of developing a novel treatment method and medical device, now poised for clinical trials and regulatory approvals.
The strategic investment from EPEI is a pivotal development for Nanobacterie, providing crucial support as the company moves into the next phase of clinical trials for its prostate cancer treatment. “EPEI’s investment is critical for us at this crucial stage of development. Their belief in our mission and technology allows us to move forward with the essential clinical trials needed to bring our treatment to patients,” said Edouard Alphandéry, CEO of Nanobacterie. “Together, we are setting a new standard in cancer treatment.”
This partnership comes at a time when Nanobacterie is gearing up to further its research and bring its groundbreaking treatment method to market. The backing by EPEI will enable Nanobacterie to continue its innovative work in this field and potentially extend its technology to other medical conditions in the future.
EP Equity Investment, separate from EP Group’s industrial holdings, focuses on enhancing its portfolio through strategic investments in both publicly traded and private companies. The firm’s acquisition of a minority stake in Nanobacterie aligns with its strategy to support high-potential businesses that lead in their respective fields.
This strategic move is also a testament to the Franco-Swiss collaboration, as AlphaOnco Swiss, a subsidiary of Nanobacterie based at the BioArk in Monthey (canton of Valais), continues to drive forward with its cutting-edge cancer treatment solutions, benefiting from the synergy of extensive research and development supported by their parent company, Nanobacterie, which recently achieved remarkable recognition in nanomedicine patent rankings by Marks and Clerk.
